436 related articles for article (PubMed ID: 26852185)
21. Nutrigenetic Interactions Might Modulate the Antioxidant and Anti-Inflammatory Status in Mastiha-Supplemented Patients With NAFLD.
Kanoni S; Kumar S; Amerikanou C; Kurth MJ; Stathopoulou MG; Bourgeois S; Masson C; Kannt A; Cesarini L; Kontoe MS; Milanović M; Roig FJ; Beribaka M; Campolo J; Jiménez-Hernández N; Milošević N; Llorens C; Smyrnioudis I; Francino MP; Milić N; Kaliora AC; Trivella MG; Ruddock MW; Medić-Stojanoska M; Gastaldelli A; Lamont J; Deloukas P; Dedoussis GV; Visvikis-Siest S
Front Immunol; 2021; 12():683028. PubMed ID: 34025683
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Phytosomal Curcumin in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial.
Panahi Y; Kianpour P; Mohtashami R; Jafari R; Simental-Mendía LE; Sahebkar A
Drug Res (Stuttg); 2017 Apr; 67(4):244-251. PubMed ID: 28158893
[TBL] [Abstract][Full Text] [Related]
23. Omega-3 fatty acids and nonalcoholic fatty liver disease in adults and children: where do we stand?
Spooner MH; Jump DB
Curr Opin Clin Nutr Metab Care; 2019 Mar; 22(2):103-110. PubMed ID: 30601174
[TBL] [Abstract][Full Text] [Related]
24. Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH, and CHC: results from a meta-analysis.
Ji HF; Sun Y; Shen L
Nutrition; 2014 Sep; 30(9):986-91. PubMed ID: 24976430
[TBL] [Abstract][Full Text] [Related]
25. Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD).
Saeed A; Dullaart RPF; Schreuder TCMA; Blokzijl H; Faber KN
Nutrients; 2017 Dec; 10(1):. PubMed ID: 29286303
[TBL] [Abstract][Full Text] [Related]
26. Citrulline decreases hepatic endotoxin-induced injury in fructose-induced non-alcoholic liver disease: an ex vivo study in the isolated perfused rat liver.
Ouelaa W; Jegatheesan P; M'bouyou-Boungou J; Vicente C; Nakib S; Nubret E; De Bandt JP
Br J Nutr; 2017 Jun; 117(11):1487-1494. PubMed ID: 28637520
[TBL] [Abstract][Full Text] [Related]
27. Antioxidant therapy and drugs interfering with lipid metabolism: could they be effective in NAFLD patients?
Musso G; Anty R; Petta S
Curr Pharm Des; 2013; 19(29):5297-313. PubMed ID: 23394094
[TBL] [Abstract][Full Text] [Related]
28. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
29. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
30. Effects of Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease-A Meta-Analysis.
Jakubczyk K; Skonieczna-Żydecka K; Kałduńska J; Stachowska E; Gutowska I; Janda K
Nutrients; 2020 Aug; 12(8):. PubMed ID: 32823621
[TBL] [Abstract][Full Text] [Related]
31. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
Faghihzadeh F; Adibi P; Hekmatdoost A
Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
[TBL] [Abstract][Full Text] [Related]
32. A Molecular Insight into the Role of Antioxidants in Nonalcoholic Fatty Liver Diseases.
Ezhilarasan D; Lakshmi T
Oxid Med Cell Longev; 2022; 2022():9233650. PubMed ID: 35602098
[TBL] [Abstract][Full Text] [Related]
33. Polyphenols in the prevention and treatment of non-alcoholic fatty liver disease: An update of preclinical and clinical studies.
Bayram HM; Majoo FM; Ozturkcan A
Clin Nutr ESPEN; 2021 Aug; 44():1-14. PubMed ID: 34330452
[TBL] [Abstract][Full Text] [Related]
34. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
[TBL] [Abstract][Full Text] [Related]
35. The potential of flavonoids in the treatment of non-alcoholic fatty liver disease.
Van De Wier B; Koek GH; Bast A; Haenen GR
Crit Rev Food Sci Nutr; 2017 Mar; 57(4):834-855. PubMed ID: 25897647
[TBL] [Abstract][Full Text] [Related]
36. Phenotypic Alteration of Hepatocytes in Non-Alcoholic Fatty Liver Disease.
Lakhani HV; Sharma D; Dodrill MW; Nawab A; Sharma N; Cottrill CL; Shapiro JI; Sodhi K
Int J Med Sci; 2018; 15(14):1591-1599. PubMed ID: 30588181
[TBL] [Abstract][Full Text] [Related]
37. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
38. Preventive effects of citrulline on Western diet-induced non-alcoholic fatty liver disease in rats.
Jegatheesan P; Beutheu S; Freese K; Waligora-Dupriet AJ; Nubret E; Butel MJ; Bergheim I; De Bandt JP
Br J Nutr; 2016 Jul; 116(2):191-203. PubMed ID: 27197843
[TBL] [Abstract][Full Text] [Related]
39. Promising therapies for treatment of nonalcoholic steatohepatitis.
Noureddin M; Zhang A; Loomba R
Expert Opin Emerg Drugs; 2016 Sep; 21(3):343-57. PubMed ID: 27501374
[TBL] [Abstract][Full Text] [Related]
40. Non-Alcoholic Fatty Liver Disease.
Brůha R
Vnitr Lek; 2019; 65(9):571-575. PubMed ID: 31635468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
